Compare Humana Inc (HUM) vs Lennar Corporation (LEN) Price & Performance

Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.

The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.

Lennar (LEN) trades at $76.13, down 1.65% on the day, with technical indicators showing bearish momentum. The stock trades below book value (P/B 0.84) and at a discount to peers (P/E 14.42), but faces headwinds from declining revenue and net income margins. Recent news highlights Berkshire Hathaway's growing stake (now 11.2% as of Sept 30, 2026) while Morgan Stanley issued a sell rating, reflecting divergent views on the housing recovery timeline.

The outlook remains challenged by high mortgage rates and weak builder sentiment, though Berkshire's accumulation suggests long-term value. Key risks include the Hunterbrook short report alleging questionable transactions and ongoing margin pressure. With earnings missing estimates for three consecutive quarters and Q3 guidance cut, near-term catalysts appear limited despite attractive valuation metrics.